Last updated on September 2018

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Brief description of study

This registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with Transfusion Dependent, IPSS low or intermediate-1-Risk Myelodysplastic Syndrome (MDS), associated to a single abnormality of the chromosome 5 [del(5q)].

The purpose of this study is to collect additional data about the safety of an oral drug (lenalidomide, Revlimid) that may have been prescribed to relieve anemia and decrease the need of blood transfusions. However, also patients affected by the MDS del(5q) who receive other treatments different from lenalidomide can be included in this study, if they agree.

Clinical Study Identifier: NCT02279654

Contact Investigators or Research Sites near you

Start Over

Associate Director Clinical Trial Disclosure

Northwick Park Hospital
Harrow, United Kingdom
  Connect »

Associate Director Clinical Trial Disclosure

Hammersmith Hospital
London, United Kingdom
  Connect »